Managing Interstitial Lung Disease

Paul W. Noble, MD; Tanzira Zaman, MD


July 27, 2020

Interstitial lung disease (ILD) is an umbrella term that describes a large, heterogeneous group of parenchymal lung disorders. The most common ILD is idiopathic pulmonary fibrosis (IPF). Although some ILDs are related to connective tissue diseases, others are associated with environmental factors, and some have an unknown, or idiopathic, course. Successful management of patients with ILD requires an accurate and specific diagnosis.

Until recently, the management of these diseases has been particularly challenging, due in part to a lack of therapeutic options.

Drs Paul Noble and Tanzira Zaman, from Cedars-Sinai Medical Center in Los Angeles, discuss how the approval of nintedanib and pirfenidone for IPF has changed the treatment paradigm, and why early identification of ILD is critical to achieve the best possible outcomes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.